3D Prediction of Patient-Specific Response

  • STATUS
    Recruiting
  • End date
    Dec 19, 2024
  • participants needed
    570
  • sponsor
    KIYATEC
Updated on 19 July 2021
cancer
cytotoxic chemotherapy
cancer chemotherapy
cancer of the ovary

Summary

This is a prospective, non-randomized, observational registry study evaluating a patient-specific ex vivo 3D (EV3D) assay for drug response using a patient's own biopsy or resected tumor tissue for assessing tissue response to therapy in patients with advanced cancers, including ovarian cancer, high-grade gliomas, and high-grade rare tumors.

Description

This protocol defines a prospective, open-label, multi-institutional, non-interventional study for the purpose of examining the Assay's clinical use and potential to impact patient outcomes. This Study will establish a registry of clinical parameters, including clinical response, clinical outcomes, Assay performance and potential utilization across multiple types of advanced cancers in consenting patients who have their tumor tissue tested by the Assay. Physicians may have access to Assay results which which predict therapeutic response to cancer drugs most often prescribed to treat the specified indications. For cancers with standard of care (SOC) cancer drug treatments, the Assay panel tests SOC systemic agents per NCCN guidelines, some of which may include both FDA approved and off-label FDA approved therapies. The Assay currently assesses the most common cancer drugs across multiple tumor types. It requires freshly obtained tumor specimen that has not been previously preserved for traditional histologic analysis. The Registry will focus initially on tumor types and agents which have been analytically validated with the Assay and determined to meet strict laboratory qualifications and standards. The Registry will collect data on a limited number of cancer types to include epithelial ovarian cancer (EOC), high-grade gliomas (HGG) limited to anaplastic astrocytoma (AA) and glioblastoma multiforme (GBM), and high-grade rare tumors (RT).

Details
Condition Ovarian disorder, Astrocytoma, Glioma, Ovarian Cancer, Glioblastoma Multiforme, Ovarian Function, Advanced Cancer, Recurrent Ovarian Cancer, Gliomas, anaplastic astrocytoma, glioblastoma, cancer advanced, ovarian carcinomas, cancer, ovarian, cancer ovarian, cancer of the ovary, astrocytoma, anaplastic, ovarian tumors
Treatment EV3D Assay
Clinical Study IdentifierNCT03561207
SponsorKIYATEC
Last Modified on19 July 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

Age 18 years and older
Diagnosis of or suspected diagnosis of EOC, HGG, high-grade RT
Individual must undergo elective surgery or biopsy to remove tumor tissue
Consideration as a candidate for systemic therapy with cytotoxic chemotherapy, targeted small molecule inhibitors or immunotherapy
Eastern Cooperative Oncology Group (ECOG) Performance Status 3
Written informed consent in accordance with institutional standards must be obtained from the patient or legal guardian

Exclusion Criteria

Inability or refusal of the patient or legal guardian to sign a written informed consent
Failure to have surgery or a biopsy as part of routine clinical practice
Refusal to have the Assay performed on their tissue
Known active cancer metastatic to the brain except for patients with brain metastases that have been treated and are considered stable
Inability or unwillingness to receive chemotherapy treatment beyond surgery
Any coincidental medical condition that, in the Investigator's opinion, would preclude participation in the study or compromise the patient's ability to give informed consent
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar
Name

Primary Contact

site
Name

0/250
Preferred Language
Other Language
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note